ArticleMacromolecular bioscience2016
Macromolecular Pt(IV) Prodrugs from Poly(organo)phosphazenes.
Article in Macromolecular bioscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Bacterial Ghosts as Innovative Transport Vehicles for Platinum-Based Anticancer Drugs.ChemMedChem · 2026Article
- Polyphosphazene-Based Nanotherapeutics.Journal of functional biomaterials · 2025Review
- Cyclo- and Polyphosphazenes for Biomedical Applications.Molecules (Basel, Switzerland) · 2022Review
- Hetero and homo α,ω-chain-end functionalized polyphosphazenes.Journal of polymer science (2020) · 2022Article
- Polyphosphazene-Based Nanocarriers for the Release of Camptothecin and Epirubicin.Pharmaceutics · 2022Article
- Main-Chain Phosphorus-Containing Polymers for Therapeutic Applications.Molecules (Basel, Switzerland) · 2020Review
- Stimuli-Responsive Phosphorus-Based Polymers.European journal of inorganic chemistry · 2019Review
- EGFR-targeting peptide-coupled platinum(IV) complexes.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The preparation of novel macromolecular prodrugs via the conjugation of two platinum(IV) complexes to suitably functionalized poly(organo)phosphazenes is presented. The inorganic/organic polymers provide carriers with controlled dimensions due to the use of living cationic polymerization and allow the preparation of conjugates with excellent aqueous solubility but long-term hydrolytic degradability. The macromolecular Pt(IV) prodrugs are designed to undergo intracellular reduction and simultaneous release from the macromolecular carrier to present the active Pt(II) drug derivatives. In vitro investigations show a significantly enhanced intracellular uptake of Pt for the macromolecular prodrugs when compared to small molecule Pt complexes, which is also reflected in an increase in cytotoxicity. Interestingly, drug-resistant sublines also show a significantly smaller resistance against the conjugates compared to clinically established platinum drugs, indicating that an alternative uptake route of the Pt(IV) conjugates might also be able to overcome acquired resistance against Pt(II) drugs. In vivo studies of a selected conjugate show improved tumor shrinkage compared to the respective Pt(IV) complex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.